

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

DANIEL J. DRUCKER, MD

OBJECTIVE — To examine the mechanisms of action, therapeutic potential, and challenges inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the treatment of type 2 diabetes.

RESEARCH DESIGN AND METHODS — The scientific literature describing the biological importance of incretin peptides and DPP-IV inhibitors in the control of glucose homeostasis has been reviewed, with an emphasis on mechanisms of action, experimental diabetes, human physiological experiments, and short-term clinical studies in normal and diabetic human subjects.

RESULTS — Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) exert important effects on β -cells to stimulate glucose-dependent insulin secretion. Both peptides also regulate β -cell proliferation and cytoprotection. GLP-1, but not GIP, inhibits gastric emptying, glucagon secretion, and food intake. The glucose-lowering actions of GLP-1, but not GIP, are preserved in subjects with type 2 diabetes. However, native GLP-1 is rapidly degraded by DPP-IV after parenteral administration; hence, degradation-resistant, long-acting GLP-1 receptor (GLP-1R) agonists are preferable agents for the chronic treatment of human diabetes. Alternatively, inhibition of DPP-IV-mediated incretin degradation represents a complementary therapeutic approach, as orally available DPP-IV inhibitors have been shown to lower glucose in experimental diabetic models and human subjects with type 2 diabetes.

CONCLUSIONS — GLP-1R agonists and DPP-IV inhibitors have shown promising results in clinical trials for the treatment of type 2 diabetes. The need for daily injections of potentially immunogenic GLP-1–derived peptides and the potential for unanticipated side effects with chronic use of DPP-IV inhibitors will require ongoing scrutiny of the risk-benefit ratio for these new therapies as they are evaluated in the clinic.

Diabetes Care 26:2929–2940, 2003

After meal ingestion, nutrient entry into the stomach and transit through the proximal gastrointestinal (GI) tract stimulates activation of neural and hormonal signals that control gastric emptying and gut motility, nutrient absorption, and hormonal regulation of energy disposal and storage. The mu-

cosal epithelium of the GI tract is one of the earliest integrators of information relevant to digestion and assimilation of nutrient loads. Highly specialized enteroendocrine cells dispersed along the length of the GI tract play an important role in controlling the rate of gastric emptying and small bowel motility, pancreatic

enzyme secretion, and the growth and differentiated absorptive function of the small and large bowel epithelium. The aim of this review is to examine our current understanding of the physiological actions of two gut hormones, glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), with an emphasis on the biological importance and pharmaceutical potential of these peptides for the treatment of type 2 diabetes.

INTRODUCTION TO THE INCRETIN CONCEPT

The development and application of the insulin radioimmunoassay to clinical investigation has permitted the assessment of β -cell secretory function after meal ingestion in normal and diabetic subjects. The observation that food ingestion or enteral glucose administration provoked a greater stimulation of insulin release compared with similar amounts of energy (glucose) infused intravenously (1,2) led to the development of the incretin concept. Hence, it was postulated that gut-derived signals stimulated by oral nutrient ingestion represent potent insulin secretagogues responsible for the augmentation of insulin release when energy is administered via the gut versus the parenteral route (3). Although several neurotransmitters and gut hormones possess incretin-like activity, the considerable evidence from immunoneutralization, antagonist, and knockout studies suggests that GIP and GLP-1 represent the dominant peptides responsible for the majority of nutrient-stimulated insulin secretion. The observation that patients with type 2 diabetes exhibit a significant reduction in the magnitude of meal-stimulated insulin release underlies the interest in determining whether defective incretin release or resistance to incretin action contributes to the pathophysiology of β -cell dysfunction in diabetic subjects.

INCRETIN SYNTHESIS, SECRETION, AND DEGRADATION

— GIP and GLP-1 are members of the glucagon peptide superfamily and share considerable amino

From the Banting and Best Diabetes Centre, Department of Medicine, Toronto General Hospital, University of Toronto, Ontario, Canada.

Address correspondence and reprint requests to Daniel J. Drucker, MD, Banting and Best Diabetes Centre, University of Toronto, Toronto General Hospital, 200 Elizabeth St., MBRW 4R-402, Toronto, Ontario, Canada M5G 2C4. E-mail: d.drucker@utoronto.ca.

Received for publication 5 May 2003 and accepted in revised form 30 June 2003.

D.J.D. is on the scientific advisory board for Amylin Pharmaceuticals, Conjuchem, and Transition Therapeutics and a consultant for Merck, Forest Labs, Bristol Myers Squibb, Triad Pharmaceuticals, Aventis, Novartis, Amylin Pharmaceuticals, and Conjuchem.

Abbreviations: DPP, dipeptidyl peptidase IV; GI, gastrointestinal; GIP, glucose-dependent insulinotropic peptide; GIPR, GIP receptor; GLP, glucagon-like peptide; GLP-1R, GLP-1 receptor.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2003 by the American Diabetes Association.




Figure 1—Structure of proglucagon and preproGIP encoding GLP-1 and GIP, respectively, is shown. The arrow designates the position of the DPP-IV-mediated cleavage after the position 2 alanine residue. GRPP, glicentin-related pancreatic peptide; IP, intervening peptide.

acid identity. GIP is a single 42-amino acid peptide encoded within a larger 153-amino acid precursor (Fig. 1) (4). GIP-secreting enteroendocrine K-cells are concentrated in the duodenum and proximal jejunum; hence, these cells are anatomically situated in an ideal location for sensing and responding to nutrient ingestion. GLP-1 is derived from a larger proglucagon precursor that encodes not only GLP-1 but also the related proglucagon-derived peptides glucagon, GLP-2, oxyntomodulin, and glicentin (Fig. 1) (5). The two forms of GLP-1 secreted after meal ingestion, GLP-1(7-37) and GLP-1(7-36)amide differ by a single amino acid. Both peptides are equipotent and exhibit identical plasma half-lives and biological activities acting through the same receptor (6,7); however, the majority (~80%) of circulating active GLP-1 appears to be GLP-1(7-36)amide (8). In contrast to the more proximal location of GIP-producing K-cells, the majority of GLP-1 is synthesized within L-cells located predominantly in the ileum and colon, although GLP-1-producing L-cells have also been identified more proximally in the duodenum and jejunum. Despite the more distal location of most L-cells, circulating levels of GLP-1 also increase rapidly within minutes of food ingestion. Hence, GLP-1 secretion from the distal gut is controlled by both neural and endocrine signals initiated by nutrient entry in the proximal GI tract, as well as by subsequent direct contact of open-type L-cells with digested nutrients. Ingestion of a mixed meal or a meal enriched with specific fats and complex carbohydrates is

particularly effective in stimulating GIP and GLP-1 release in human subjects (9,10). Although the vagal nerve, via M1 muscarinic receptors, and several neuroendocrine peptides contribute to the regulation of GLP-1 release in rodents (11,12), the factors responsible for rapid nutrient-stimulated GLP-1 release in human subjects are largely unknown.

The levels of total circulating GIP and GLP-1 immunoreactivity reflect a combination of intact, full-length active and NH₂-terminally truncated inactive peptides, with GIP(3-42) and GLP-1(9-36)amide contributing to >50% of total immunoreactive GIP and GLP-1 in both the fasting and the postprandial states (13,14). Plasma levels of both GIP and GLP-1 immunoreactivity are low in the fasting state and rise rapidly within minutes of food ingestion. Initial studies of circulating levels of GIP and GLP-1 relied principally on radioimmunoassays incapable of distinguishing the biologically active full-length peptides from inactive COOH-terminal peptide fragments generated as a result of proteolytic cleavage. Studies have demonstrated that both GIP and GLP-1 were cleaved at the position 2 alanine by the widely expressed aminopeptidase dipeptidyl peptidase IV (DPP-IV) (15,16). These findings have prompted a reanalysis of the circulating molecular forms of GIP and GLP-1 using newer radioimmunoassays more specific for the full-length bioactive peptides in normal and diabetic subjects.

The disappearance of exogenously administered GIP and GLP-1 has been studied in normal and diabetic human

subjects using antisera capable of discriminating the full-length from the NH₂-terminally cleaved peptides. The *t*_{1/2} of infused GIP is ~7 and 5 min in normal and diabetic human subjects, respectively (14). In contrast, the *t*_{1/2} of exogenously infused intact GLP-1 is considerably shorter (13), with intravenously administered GLP-1 eliminated with a half-life of ~2 min in both normal and obese diabetic human subjects (17). Although the NH₂-terminally truncated peptides GIP(3-42) and GLP-1(9-36)amide function as weak antagonists of their respective receptors (18,19), there is little evidence that these truncated peptides exert physiologically important actions in human subjects *in vivo*. Despite observations that GLP-1(9-36)amide may function as an activator of insulin-independent glucose clearance in pigs (20), this peptide does not exert significant glucose-lowering properties in human subjects (21).

Circulating levels of GIP(1-42) are normal or slightly increased in type 2 diabetic subjects in the basal or postprandial states (22). In contrast, subjects with diabetes or impaired glucose tolerance exhibit modest but significant reductions in levels of meal-stimulated circulating GLP-1 (22,23). Furthermore, meal-induced increases in GIP and GLP-1 secretion are inversely correlated with the extent of insulin resistance detected in human subjects (24). The lower levels of circulating GLP-1 detected in diabetic subjects are not attributable to altered GLP-1 clearance (17). Whether levels of meal-stimulated GLP-1 may be restored toward normal with improved control of diabetes remains unknown.

GIP ACTION: INSIGHTS FROM PRECLINICAL AND HUMAN STUDIES

GIP was originally observed to inhibit gastric acid secretion (gastric inhibitory polypeptide), predominantly at supraphysiological dosages. Subsequent studies have demonstrated potent glucose-dependent insulin stimulatory effects from GIP administration in dogs and rodents. GIP also regulates fat metabolism in adipocytes, including stimulation of lipoprotein lipase activity, fatty acid incorporation, and fatty acid synthesis (25). Unlike GLP-1, GIP does not inhibit glucagon secretion or gastric emptying. GIP does promote β-cell proliferation and cell survival


in islet cell line studies (26,27); whether GIP also induces β -cell growth or survival in diabetic rodents remains unclear.

The physiological actions of GIP have been deduced using GIP peptide antagonists, GIP receptor antisera, and GIP receptor knockout mice. NH_2 -terminally truncated or modified GIP peptides such as GIP(6-30)amide, GIP(7-30)amide, or (Pro³)GIP block GIP binding to the GIP receptor with varying effectiveness, and attenuate the insulinotropic effects of exogenous GIP in vitro and endogenous GIP in vivo (28–30). Similarly, immunopurified antisera against the extracellular domain of the GIP receptor block GIP binding and attenuate glucose-dependent insulin secretion after oral glucose loading in rats and mice (31,32). Complementary evidence for the incretin-like actions of GIP is derived from analysis of GIP receptor-null mice, which exhibit mild glucose intolerance after oral glucose loading (33). Surprisingly, $\text{GIPR}^{-/-}$ mice exhibit resistance to diet-induced obesity after months of high-fat feeding. Moreover, the $\text{GIPR}^{-/-}$ genotype attenuates obesity in the *ob/ob* mouse, possibly because of reduced fat storage and altered lipid metabolism as a direct result of absent GIP receptor (GIPR) action in adipocytes (34). Whether GIPR action significantly modulates adipocyte biology, lipoprotein synthesis, and weight accretion in humans is not known.

In contrast to the potent glucose-lowering actions of GIP in normal rodents, exogenous GIP administration is comparatively less insulinotropic in obese diabetic rodents. GIP levels are increased in some models of experimental rodent diabetes, and continuous GIP infusion for 4 h produces GIPR desensitization in normal rats (35). ZDF rats exhibit normal levels of GIP, absent insulinotropic responses to exogenous GIP and reduced expression of the GIPR in isolated islets (36). Recent studies with more potent GIP analogs engineered for resistance to DPP-IV have demonstrated improved insulinotropic and glucose-lowering properties after peptide administration to both normal and diabetic rodents (37–39).

Infusion of porcine or human GIP into patients with type 2 diabetes has produced variable insulinotropic responses, ranging from preserved (40) to attenuated or near absent insulin secretion (41–45). The potential for β -cell GIP responsiveness to improve with treatment in type 2 dia-

Figure 2—The major biological actions of GLP-1.



betic subjects is intriguing, but has not been extensively examined (46). The GIP defect in insulin secretion seems most pronounced in the late phase of insulin secretion (47). Moreover, ~50% of normoglycemic first-degree relatives of type 2 diabetic subjects exhibit reduced insulin secretion after exogenous GIP infusion (48). Hence the reduced insulinotropic action of GIP in diabetes likely reflects a combination of genetic and acquired defects. Whether the pancreatic effects of GIP on β -cell proliferation and survival are also diminished in experimental or clinical diabetes is not known.

GLP-1 PRECLINICAL STUDIES AND PHYSIOLOGICAL ACTIONS —

Original observations elucidating a role for GLP-1 in the potentiation of glucose-dependent insulin secretion (49–51) and insulin gene expression (52) were followed by experiments demonstrating that GLP-1 also inhibits glucagon secretion (53,54) and gastric emptying (55) (Fig. 2). Acute intracerebroventricular (56) injection of GLP-1 or GLP-1 receptor (GLP-1R) agonists produces transient reduction in food intake, whereas more prolonged intracerebroventricular or peripheral GLP-1R agonist administration is associated with weight loss in some (57–60), but not all (61) studies. GLP-1 actions on food intake appear related in part to overlapping actions on central nervous system aversive signaling pathways, which remains a topic of intense interest (62–66). In contrast to GIP, the spectrum of actions

delineated for GLP-1 that promote glucose lowering (regulation of insulin and glucagon secretion, inhibition of gastric emptying, and reduction of food intake) appear comparable in diabetic versus nondiabetic animals of various ages.

GLP-1 exerts actions on β -cells independent of acute stimulation of insulin secretion. Incubation of isolated rat islet cells with GLP-1 recruited nonresponsive glucose-resistant β -cells to a functional state of glucose-responsive insulin secretion, designated glucose competence (67,68). GLP-1R agonists also promote insulin biosynthesis, β -cell proliferation, and survival (69–71), and stimulate differentiation of exocrine cells or islet precursors toward a more differentiated β -cell phenotype (72–74). The GLP-1R-dependent augmentation of β -cell mass has been demonstrated in diverse experimental models, including neonatal rats administered streptozotocin and exendin-4 (75) and normal Wistar rats ages 6 and 22 months infused with native GLP-1 for 5 days (76). Similarly, GLP-1R agonists promote β -cell proliferation and expansion of functional islet mass after partial pancreatectomy in rats aged 4–5 weeks (69) or in neonatal rat pups subjected to experimental intrauterine growth retardation (77). The expansion of β -cell mass after GLP-1R agonist administration prevents or delays the occurrence of diabetes in *db/db* mice (78) and GK diabetes-prone rats (79). Furthermore, the induction of islet proliferation after GLP-1R activation has been seen with a broad range of GLP-1R agonists,

including native GLP-1 (76,79,80), exendin-4, NN2211 (81), and CJC-1131 (82).

GLP-1R agonists also activate anti-apoptotic pathways coupled to a reduction in β -cell death. *db/db* mice treated with exendin-4 for 2 weeks exhibited decreased numbers of apoptotic β -cells, reduced pancreatic caspase-3 activation, and increased Akt1 expression (78). Reduced islet apoptosis has been observed in GLP-1-treated Zucker diabetic rats (83) and in exendin-4-treated mice after streptozotocin-induced β -cell injury (70). The anti-apoptotic actions of GLP-1R agonists are likely direct, as GLP-1 reduced peroxide-induced apoptosis in Min6 insulinoma cells (84) and exendin-4 significantly attenuated cytokine-induced apoptosis in cultures of purified rat β -cells (70). Hence, the GLP-1R-dependent activation of both proliferative and anti-apoptotic pathways in the pancreas provides complementary mechanisms for preserving and enhancing functional β -cell mass.

The physiological importance of GLP-1 action has been studied using GLP-1R antagonists. Infusion of the peptide exendin(9-39) into rats, mice, baboons, and humans produces an increase in fasting glucose and glycemic excursion after oral glucose loading in association with reduced levels of circulating insulin (32,85–87). Exendin(9-39) also produces abnormal glycemic excursion after nonenteral glucose loading in mice (32). These findings illustrate that transient disruption of GLP-1 action consistently perturbs the incretin and nonincretin actions of GLP-1 on glucoregulation. Acute intracerebroventricular injection of exendin(9-39) increases food intake in satiated rats (56), whereas repeated daily intracerebroventricular administration of exendin(9-39) increases food intake and weight gain (57). Similarly, acute exendin(9-39) administration increases gastric emptying after glucose ingestion in fistulized rats (88). Comparable studies with exendin(9-39) in humans have demonstrated the essential role of GLP-1 action for glucose control via regulation of glucagon and insulin secretion (89,90). Hence, the majority of actions observed after exogenous administration of GLP-1R agonists are also physiologically essential, as revealed by acute interruption of GLP-1 action.

Genetic disruption of GLP-1R expres-

sion in mice has produced comparable insights into the physiological importance of GLP-1 action. GLP-1R^{-/-} mice exhibit abnormal glucose tolerance after both oral and intraperitoneal glucose challenge in association with diminished glucose-stimulated insulin secretion. In contrast, insulin sensitivity and the glucagon response to glucose loading or hypoglycemia are normal in the absence of GLP-1R signaling (91). Consistent with the cardiovascular effects of GLP-1 in rodents, GLP-1R^{-/-} mice exhibit defective cardiovascular responses to stress (92). Despite the potential importance of GLP-1R circuits for transducing the anorectic action of leptin (93), GLP-1R^{-/-} mice retain normal to enhanced leptin sensitivity (94,95). Similarly, food intake and body weight are not significantly perturbed in GLP-1R^{-/-} mice in the CD1 genetic background (96,97). In contrast, GLP-1R^{-/-} mice manifest subtle but detectable abnormalities in islet number and size (98) and exhibit a defective β -cell regenerative response to partial pancreatectomy (99). Hence, GLP-1R actions are physiologically important for the growth and adaptive regeneration of murine β -cells.

GLP-1R agonists and experimental models of diabetes

The glucose-lowering action of GLP-1 delineated in nondiabetic animals has been demonstrated in multiple models of experimental diabetes. A 48-h infusion of native GLP-1 lowered blood glucose in association with increased levels of circulating insulin, islet insulin content, and insulin mRNA in Wistar rats aged 22 months (100), and perfused pancreas studies have demonstrated GLP-1-dependent augmentation of insulin secretion in ZDF rats of diverse genetic backgrounds (101–103). Similarly, exendin-4 lowered glucose in *db/db* and *ob/ob* mice, ZDF rats, and diabetic rhesus monkeys in acute and chronic experiments (78,104,105) and the GLP-1 analog NN211 improved glycemic control in pigs, rats, and mice (60,81,106). Remarkably, glucose tolerance remained significantly improved in ZDF rats for weeks after a 48-h infusion of native GLP-1 (107). This “memory effect” for sustained improvement of glycemic control was also observed in *db/db* mice after discontinuation of therapy with CJC-1131, an albumin-bound GLP-1R agonist (82).

GLP-1 action in human subjects

The majority of GLP-1 actions delineated in preclinical experiments have also been demonstrated in human studies. Infusion of GLP-1(7-36)amide into normal human subjects stimulated insulin secretion, reduced glucagon secretion, and significantly reduced blood glucose in the fasting state after glucose loading or meal ingestion (6,50,108). In contrast to GIP, the insulinotropic and glucose-lowering actions of GLP-1 are preserved in human subjects with type 2 diabetes (45,109) in both the fasting and the postprandial states (7). Similarly, GLP-1 inhibits gastric acid secretion (110,111) and gastric emptying in humans (55) and the GLP-1-dependent attenuation of gastric emptying contributes to decreased glycemic excursion and, consequently, reduced glucose-stimulated insulin secretion (112,113). Consistent with the importance of gastric emptying and glucagon secretion for glycemic control, GLP-1 also lowers blood glucose in type 1 diabetic subjects (114–116). Analogous to studies demonstrating the induction of glucose competence in rodent β -cells, GLP-1 infusion enhances β -cell function and insulin secretory dynamics in human subjects with impaired glucose tolerance or type 2 diabetes (117–119). GLP-1 may also enhance glucose clearance in humans (120,121); however, the majority of these actions are likely mediated indirectly through effects on insulin and glucagon (122–124). Although several reports have described the effects of GLP-1 on muscle, liver, and fat cells, experimental evidence demonstrating expression of the GLP-1 receptor in these tissues *in vivo* is lacking. Hence, the indirect actions of GLP-1, leading to improvement in glycemic control and reduction in free fatty acids, may explain observations of improved insulin sensitivity in GLP-1-treated diabetic subjects (125).

The effect of GLP-1 in restoring glucose competence in rodent islets has prompted studies of GLP-1 action and β -cell function in type 2 diabetic patients. Insulin-treated diabetic subjects previously classified as “sulfonlylurea nonresponders” exhibited β -cell GLP-1 responsiveness, with lowering of fasting and postprandial glucose in association with enhanced insulin secretion (126). Patients treated with both GLP-1 and glibenclamide exhibited a greater degree of glucose reduction compared with the ef-

fect of either agent alone (127). Similarly, the combination of GLP-1 and metformin was shown in a 48-h crossover study to be more effective for lowering blood glucose than monotherapy with either agent alone (128).

The GLP-1–dependent suppression of glucagon secretion raises the possibility that GLP-1 therapy will be associated with an increased risk of hypoglycemia and potentially defective counterregulation if glucagon secretion remains suppressed in the face of GLP-1–linked hypoglycemia. Rapid gastric emptying may be associated with enhanced GLP-1 release and an increased risk of hypoglycemia in postgastrectomy patients (129). Similarly, acute administration of GLP-1 (80 nmol) to nondiabetic subjects in the fasted state produced mild relative hypoglycemia in some subjects (mean glucose ~ 3.5 mmol/l) (130). Nevertheless, appropriate glucagon responses to hypoglycemia do not appear to be blunted in GLP-1–treated subjects (130), and GLP-1 infusion does not impair normal counterregulatory responses to hypoglycemia in healthy human subjects (131). Hence, the risk of hypoglycemia seems modest in type 2 diabetic subjects treated with GLP-1R agonists alone.

The demonstration that both intracerebroventricular and peripheral administration of GLP-1R agonists induces weight loss in preclinical experiments has fostered interest in the potential actions of these agents to diminish appetite and reduce weight gain in overweight human subjects. The majority of human studies have examined appetite and food ingestion over short (24-h) time periods after single-dose injection or continuous infusion of GLP-1. Small but statistically significant reductions in appetite and meal ingestion have been recorded in studies of normal, obese, and diabetic GLP-1–treated subjects (132–136). A meta-analysis of available data from 115 subjects demonstrated significant GLP-1–dependent reductions in energy consumption in lean and overweight subjects (137). The acute reduction in food consumption and inhibition of gastric emptying has been detected even with physiological increases in levels of circulating GLP-1 (136). Administration of GLP-1 via continuous subcutaneous infusion for 6 weeks to obese diabetic subjects was associated with reduced appetite and a small but significant mean 1.9-kg

weight loss (125). Hence, GLP-1 therapy in human subjects appears associated with prevention of weight gain or modest weight loss; however, long-term data are not yet available.

Although single or repeated subcutaneous injections of native GLP-1 decrease blood glucose in human subjects (138,139), the glucose-lowering effects are transient and no longer evident 1–2 h after peptide injection (140,141). Furthermore, continuous enhancement of GLP-1 action for 24 h/day appears superior for glucose control compared with peptide infusion for 16 h (142). Continuous intravenous or subcutaneous infusion of GLP-1 in short- and long-term studies has been shown to be highly effective in lowering blood glucose in diabetic subjects (125,143,144), but this intensive and expensive approach has major limitations for the treatment of large numbers of diabetic patients. The rapid degradation and clearance of native endogenous and exogenously administered GLP-1 (145) have spurred the clinical development of degradation-resistant GLP-1 analogs with longer durations of action *in vivo*.

Exendin-4 is a naturally occurring 39–amino acid GLP-1R agonist isolated from the salivary gland venom of the lizard *Heloderma suspectum* (146). Exendin-4 exhibits 53% amino acid identity to mammalian GLP-1 (146,147), yet binds to and activates the GLP-1 receptor. Furthermore, exendin-4 is highly resistant to the proteolytic activity of DPP-IV and exhibits a longer duration of action *in vivo*. Intravenous infusion of exendin-4 lowered fasting and postprandial blood glucose in normal healthy volunteers and was associated with a 19% reduction in calorie consumption assessed during a single test meal (148). Exendin-4 exerted similar effects on insulin secretion after acute intravenous infusion in diabetic subjects (149), and subcutaneous daily administration of exendin-4 to subjects with type 2 diabetes significantly reduced blood glucose and HbA_{1c} (a decline from 9.1 to 8.3%) over a 1-month treatment period (150). Exendin-4 has been evaluated in eight phase 2 trials in 323 individuals with type 2 diabetes who received dosages of 0.05–2.0 $\mu\text{g}/\text{kg}$ subcutaneously. Nausea and vomiting were the principal side effects observed (151). A 4-week treatment period produced a significant reduction in HbA_{1c} levels, with sustained reduction in postprandial gly-

cemia maintained over the 28-day treatment period.

Exendin-4 treatment (0.08 $\mu\text{g}/\text{kg}$ s.c., b.i.d. or t.i.d.) over 1 month was evaluated in 109 patients treated with sulfonylureas or metformin, alone or in combination. The treatment was generally well tolerated, with three subjects withdrawing in the first 12 days because of nausea. At the end of the study period, a significant reduction was observed in levels of serum fructosamine, HbA_{1c}, and mean postprandial glucose, but no significant change was noted in body weight or serum lipids (152). Antibodies against exendin-4 were detected in 19% of treated subjects; however, the antibodies did not affect treatment responses. In all, 15% of patients experienced hypoglycemia; all of these subjects received sulfonylureas plus exendin-4 (152). Exendin-4, recently renamed exenatide, is currently being evaluated for the treatment of type 2 diabetes in phase 3 trials in combination with metformin, sulfonylurea agents, or both.

NN2211 (liraglutide) is a fatty acid–linked DPP-IV–resistant derivative of GLP-1 designed for subcutaneous administration that exhibits a pharmacokinetic profile compatible with once-daily injection (153). NN2211 reduced fasting and postprandial glycemia in diabetic subjects after a single 10 $\mu\text{g}/\text{kg}$ subcutaneous injection at 11:00 P.M., in association with inhibition of gastric emptying and reduced levels of circulating glucagon (154). NN2211 has been tested in phase 2 clinical trials. Additional approaches for prolonging the duration of action of GLP-1 derivatives include the use of albumin-bound GLP-1 molecules (82) and sustained release exendin-4 preparations; however, human data with these pharmaceutical approaches is currently limited.

Inhibition of DPP-IV for the treatment of type 2 diabetes

The observation that GLP-1 and GIP are rapidly cleaved at the position 2 alanine leading to inactivation of their biological activity (15,16) has fostered interest in the development of inhibitors of DPP-IV, the principal enzyme responsible for incretin inactivation (155,156). DPP-IV is but one member of a large family of related enzymes with overlapping enzyme specificity; however, adenosine deaminase affinity chromatography that specifically binds DPP-IV removes 95% of DPP-IV–

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.